Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Barriers to Treatment of HCV in Primary Care

Hepatol Int; ePub 2018 Oct 30; Johnson, et al

Reimbursement is a major barrier to primary care practitioner treatment of hepatitis C virus (HCV) infection, along with purported barriers such as complexity of the patients, time commitment, and the need for expertise. This according a recent nationwide survey of general practitioners that sought to identify barriers to HCV treatment among general practitioners. Among the details:

  • 3,817 general practitioners were surveyed; 925 (24.2%) participated.
  • 187 (21%) practitioners indicated they prescribed HCV medications.
  • 620 (70%) indicated that no general practitioner in their practice had interest in managing HCV therapy.
  • HCV training was associated with increased prescribing activity.
  • Inadequate reimbursement (44%), too few HCV patients (40%), and caseload with other patients (40%) were the most frequently identified barriers to treatment.
  • A lack of awareness to the prevalence of HCV in the general population was also identified as an important barrier.


Johnson S, Aluzaite K, Taar A, Schultz M. Identifying barriers to treatment of HCV in the primary care setting. [Published online ahead of print October 30, 2018]. Hepatol Int. doi:10.1007/s12072-018-9902-x.